Biogen Idec Inc (BIIB) 327.11 $BIIB
After Yesterday's Decline of 1.50%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 11, 3:46PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $324.74 to a high of $332.81. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $325.99 on volume of 921,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Stocks Show Modest Losses; Biotechs Pressured Again
at Investor's Business Daily - Thu Sep 11, 1:46PM CDT
Major averages showed modest losses with a little over one hour remaining in Thursday's session. The Nasdaq lost 0.2%, hurt somewhat by a fresh round of selling in biotechland. The Dow Jones industrial average and S&P 500 gave up 0.2% and 0.1%,...
Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs
at The Street - Thu Sep 11, 9:02AM CDT
Here are some numbers that may help you navigate the volatile and expensive biotech sector.
New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA(R) (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients
Business Wire - Thu Sep 11, 6:30AM CDT
--- Positive Clinical and MRI Outcomes in Newly Diagnosed Patients -
PLEGRIDY(TM) (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients
Business Wire - Thu Sep 11, 6:30AM CDT
Today Biogen Idec (NASDAQ: BIIB) announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY(TM) (peginterferon beta-1a) were maintained in people with relapsing forms of multiple sclerosis (RMS) beyond the first year of the study. These results were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) in Boston.
Why Receptos Inc. Shares Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 10, 2:49PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Receptos , a clinical-stage...
Stocks Turn Higher After Soft Start; U.S. Silica Jumps
at Investor's Business Daily - Wed Sep 10, 12:25PM CDT
Stocks turned higher in early afternoon trade Wednesday after a soft open. The Nasdaq led the way, rising 0.5%. The Dow Jones industrial average and S&P 500 added 0.1% each. Volume on the NYSE and Nasdaq was tracking 5% to 10% higher than Tuesday's...
Receptos MS Drug Yields More Good Data; Stock Jumps
at Investor's Business Daily - Wed Sep 10, 10:58AM CDT
Biotech Receptos (RCPT) shot up more than 14% in morning trading on the stock market today, just shy of an all-time high, after it released more good data from a mid-stage clinical trial of its multiple-sclerosis drug. Receptos filed a late-breaking...
Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 10, 10:17AM CDT
AbbVie's (ABBV) collaboration agreement with Infinity Pharmaceuticals (INFI) was one of the top stories in the biotech sector last week.
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms
Business Wire - Wed Sep 10, 6:00AM CDT
--- Patients Most Uncomfortable Engaging in Candid Dialogue about More Private Symptoms -
J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig
at The Street - Mon Sep 08, 7:48AM CDT
Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.
Why Baxter International Offers Great Reward for Minimal Risk
at The Street - Mon Sep 08, 5:00AM CDT
Wall Street is wrong to discount Baxter's value-creating potential.
Indexes Trim Losses But Remain Lower At Midday
at Investor's Business Daily - Fri Sep 05, 11:04AM CDT
The stock market came off morning lows at midday Friday, but remained lower as some notable leaders came under fire. The Nasdaq fell 0.3% while the S&P 500 and the Dow Jones industrial average were down 0.1%. Volume was running higher on the NYSE and...
Upcoming Conferences, Dividends, Regulatory Disclosures, and Acquisitions - Research Reports on Medtronic, Humana, Shire, Biogen and Covidien
PR Newswire - Fri Sep 05, 8:05AM CDT
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Humana Inc. (NYSE: HUM), Shire Plc (NASDAQ: SHPG), Biogen Idec Inc. (NASDAQ: BIIB) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6245-100free.
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 2.70%
Comtex SmarTrend(R) - Thu Sep 04, 3:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.78 to a high of $344.44. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $339.18 on volume of 827,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Diplomat to distribute Plegridy(TM) (peginterferon beta-1a) for treatment of multiple sclerosis
PR Newswire - Thu Sep 04, 3:42PM CDT
Diplomat, the nation's largest independent specialty pharmacy, announced that it will distribute Plegridy(TM) (peginterferon beta-1a). Manufactured by Biogen Idec, Plegridy(TM) was approved on August 15, 2014 by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (RMS). Plegridy is the only pegylated beta interferon approved for use in RMS and is dosed once every two weeks. Plegridy can be administered subcutaneously with the Plegridy Pen, a new, ready-to-use autoinjector, or a prefilled syringe.
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
5 Things Biogen Idec Inc's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 03, 8:17AM CDT
Biogen Idec held a conference call to go along with the release of second quarter earnings. Here are five things that management said on the call about Biogen Idec's ongoing prospects (quotes courtesy of S&P Capital IQ ). George Scangos...
After Yesterday's Decline of 1.50%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 11, 3:46PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $324.74 to a high of $332.81. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $325.99 on volume of 921,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Stocks Show Modest Losses; Biotechs Pressured Again
at Investor's Business Daily - Thu Sep 11, 1:46PM CDT
Major averages showed modest losses with a little over one hour remaining in Thursday's session. The Nasdaq lost 0.2%, hurt somewhat by a fresh round of selling in biotechland. The Dow Jones industrial average and S&P 500 gave up 0.2% and 0.1%,...
Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs
at The Street - Thu Sep 11, 9:02AM CDT
Here are some numbers that may help you navigate the volatile and expensive biotech sector.
New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA(R) (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients
Business Wire - Thu Sep 11, 6:30AM CDT
--- Positive Clinical and MRI Outcomes in Newly Diagnosed Patients -
PLEGRIDY(TM) (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients
Business Wire - Thu Sep 11, 6:30AM CDT
Today Biogen Idec (NASDAQ: BIIB) announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY(TM) (peginterferon beta-1a) were maintained in people with relapsing forms of multiple sclerosis (RMS) beyond the first year of the study. These results were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) in Boston.
Why Receptos Inc. Shares Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 10, 2:49PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Receptos , a clinical-stage...
Stocks Turn Higher After Soft Start; U.S. Silica Jumps
at Investor's Business Daily - Wed Sep 10, 12:25PM CDT
Stocks turned higher in early afternoon trade Wednesday after a soft open. The Nasdaq led the way, rising 0.5%. The Dow Jones industrial average and S&P 500 added 0.1% each. Volume on the NYSE and Nasdaq was tracking 5% to 10% higher than Tuesday's...
Receptos MS Drug Yields More Good Data; Stock Jumps
at Investor's Business Daily - Wed Sep 10, 10:58AM CDT
Biotech Receptos (RCPT) shot up more than 14% in morning trading on the stock market today, just shy of an all-time high, after it released more good data from a mid-stage clinical trial of its multiple-sclerosis drug. Receptos filed a late-breaking...
Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 10, 10:17AM CDT
AbbVie's (ABBV) collaboration agreement with Infinity Pharmaceuticals (INFI) was one of the top stories in the biotech sector last week.
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms
Business Wire - Wed Sep 10, 6:00AM CDT
--- Patients Most Uncomfortable Engaging in Candid Dialogue about More Private Symptoms -
J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig
at The Street - Mon Sep 08, 7:48AM CDT
Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.
Why Baxter International Offers Great Reward for Minimal Risk
at The Street - Mon Sep 08, 5:00AM CDT
Wall Street is wrong to discount Baxter's value-creating potential.
Indexes Trim Losses But Remain Lower At Midday
at Investor's Business Daily - Fri Sep 05, 11:04AM CDT
The stock market came off morning lows at midday Friday, but remained lower as some notable leaders came under fire. The Nasdaq fell 0.3% while the S&P 500 and the Dow Jones industrial average were down 0.1%. Volume was running higher on the NYSE and...
Upcoming Conferences, Dividends, Regulatory Disclosures, and Acquisitions - Research Reports on Medtronic, Humana, Shire, Biogen and Covidien
PR Newswire - Fri Sep 05, 8:05AM CDT
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Humana Inc. (NYSE: HUM), Shire Plc (NASDAQ: SHPG), Biogen Idec Inc. (NASDAQ: BIIB) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6245-100free.
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 2.70%
Comtex SmarTrend(R) - Thu Sep 04, 3:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.78 to a high of $344.44. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $339.18 on volume of 827,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Diplomat to distribute Plegridy(TM) (peginterferon beta-1a) for treatment of multiple sclerosis
PR Newswire - Thu Sep 04, 3:42PM CDT
Diplomat, the nation's largest independent specialty pharmacy, announced that it will distribute Plegridy(TM) (peginterferon beta-1a). Manufactured by Biogen Idec, Plegridy(TM) was approved on August 15, 2014 by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (RMS). Plegridy is the only pegylated beta interferon approved for use in RMS and is dosed once every two weeks. Plegridy can be administered subcutaneously with the Plegridy Pen, a new, ready-to-use autoinjector, or a prefilled syringe.
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
5 Things Biogen Idec Inc's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 03, 8:17AM CDT
Biogen Idec held a conference call to go along with the release of second quarter earnings. Here are five things that management said on the call about Biogen Idec's ongoing prospects (quotes courtesy of S&P Capital IQ ). George Scangos...
